SG11201901584UA - Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof - Google Patents

Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof

Info

Publication number
SG11201901584UA
SG11201901584UA SG11201901584UA SG11201901584UA SG11201901584UA SG 11201901584U A SG11201901584U A SG 11201901584UA SG 11201901584U A SG11201901584U A SG 11201901584UA SG 11201901584U A SG11201901584U A SG 11201901584UA SG 11201901584U A SG11201901584U A SG 11201901584UA
Authority
SG
Singapore
Prior art keywords
monoclonal antibody
pharmaceutical composition
pdl
seq
amino acid
Prior art date
Application number
SG11201901584UA
Inventor
Baiyong Li
Yu Xia
Zhongmin Maxwell Wang
Peng Zhang
Original Assignee
Akeso Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akeso Biopharma Inc filed Critical Akeso Biopharma Inc
Publication of SG11201901584UA publication Critical patent/SG11201901584UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7019—Ischaemia

Abstract

Anti-PD1 Monoclonal Antibody, Pharmaceutical Composition Thereof and Use Thereof An anti-PDl (programmed cell death 1) monoclonal antibody or an antigen-binding fragment thereof, a pharmaceutical composition thereof and use thereof. The heavy chain variable region of the monoclonal antibody comprises CDRs (complementary determining region) of amino acid sequences as shown in SEQ ID NO:9-11; and/or the light chain variable region of the monoclonal antibody comprises CDRs of amino acid sequences as shown in SEQ ID NO: 12-14. The monoc1onal antibody can bind to PDl specifically, relieve immunosuppression of PDl on an organism specifically and activate T lymphocytes. [Figure 2]
SG11201901584UA 2016-08-23 2017-08-22 Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof SG11201901584UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610705763.5A CN106977602B (en) 2016-08-23 2016-08-23 A kind of anti-PD1 monoclonal antibodies, its medical composition and its use
PCT/CN2017/098465 WO2018036472A1 (en) 2016-08-23 2017-08-22 Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof

Publications (1)

Publication Number Publication Date
SG11201901584UA true SG11201901584UA (en) 2019-03-28

Family

ID=59340342

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901584UA SG11201901584UA (en) 2016-08-23 2017-08-22 Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof

Country Status (15)

Country Link
US (1) US20190321466A1 (en)
EP (1) EP3505535A4 (en)
JP (1) JP7082620B2 (en)
KR (1) KR102469286B1 (en)
CN (1) CN106977602B (en)
AU (1) AU2017316255B2 (en)
BR (1) BR112019003775A2 (en)
CA (1) CA3034849A1 (en)
EA (1) EA201990570A1 (en)
IL (1) IL264956B2 (en)
MX (1) MX2019002268A (en)
NZ (1) NZ751902A (en)
SG (1) SG11201901584UA (en)
WO (1) WO2018036472A1 (en)
ZA (1) ZA201901781B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170135860A (en) 2015-03-13 2017-12-08 싸이톰스 테라퓨틱스, 인크. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of using them
BR112018000768A2 (en) 2015-07-13 2018-09-25 Cytomx Therapeutics Inc anti-pd-1 antibodies, activatable anti-pd-1 antibodies and methods of use
RS63125B1 (en) 2015-11-03 2022-05-31 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
CN106977602B (en) * 2016-08-23 2018-09-25 中山康方生物医药有限公司 A kind of anti-PD1 monoclonal antibodies, its medical composition and its use
CN106967172B (en) 2016-08-23 2019-01-08 康方药业有限公司 The anti-PD-1 bifunctional antibody of anti-CTLA 4-, its medical composition and its use
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
CN109425736B (en) * 2017-08-25 2021-04-09 北京百普赛斯生物科技股份有限公司 Method and kit for detecting blood concentration of PD-1antibody
CN116850284A (en) * 2017-09-20 2023-10-10 瑞泽恩制药公司 Immunotherapeutic methods for patients whose tumors bear high load of passenger gene mutations
CN112584901A (en) * 2018-04-04 2021-03-30 真和制药有限公司 Methods and compositions for blocking interactions between non-glycosylated PD-1 polypeptides
IL278400B2 (en) 2018-05-07 2024-03-01 Genmab As Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer
AU2019305857A1 (en) * 2018-07-18 2021-02-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Drug combination of quinoline derivative and antibody
CN109053889B (en) * 2018-07-25 2019-06-21 博奥信生物技术（南京）有限公司 A kind of anti-human PD1 monoclonal antibody and purposes
CN109053895B (en) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 Bifunctional antibody for resisting PD-1-VEGFA, pharmaceutical composition and application thereof
US20220175815A1 (en) 2019-04-03 2022-06-09 Orega Biotech Combination therapies based on pd1 and il-17b inhibitors
CN110373415B (en) * 2019-06-12 2023-06-09 安徽省昂普拓迈生物科技有限责任公司 Aptamer specifically binding to PD-L1 protein and application thereof
EP3998081A4 (en) 2019-07-05 2023-07-12 Ono Pharmaceutical Co., Ltd. Treatment of hematologic cancer with pd-1/cd3 dual specificity protein
US20220267444A1 (en) * 2019-08-02 2022-08-25 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-pd-1 antibody and medical use thereof
WO2021025140A1 (en) 2019-08-08 2021-02-11 小野薬品工業株式会社 Dual-specific protein
CN110903391B (en) * 2019-10-25 2021-05-28 东大生物技术(苏州)有限公司 Group of PD-L1 monoclonal antibodies and medical application thereof
CN113004408B (en) * 2019-12-20 2022-07-01 广东菲鹏制药股份有限公司 Anti-human apoptosis factor-1 monoclonal antibody
EP4110810A1 (en) 2020-02-28 2023-01-04 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
IL297432A (en) * 2020-04-22 2022-12-01 Akeso Biopharma Inc Anti-cd73-anti-pd-1 bispecific antibody and use thereof
MX2022013620A (en) 2020-04-29 2023-01-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Bifunctional protein against pd-1 and tgf-î².
CN113754767A (en) * 2020-06-03 2021-12-07 上海恒润达生生物科技股份有限公司 Anti-human PD-1 antibodies and uses thereof
WO2022068891A1 (en) * 2020-09-30 2022-04-07 苏州沙砾生物科技有限公司 Pd-1 antibody, and preparation method therefor and application thereof
KR20230110274A (en) 2020-11-17 2023-07-21 씨젠 인크. Methods of treating cancer with a combination of tucatinib and an anti-PD-1/anti-PD-L1 antibody
CN113336848B (en) * 2021-02-03 2022-08-19 上海莱馥医疗科技有限公司 anti-PD-1 antibody and application thereof
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
CN115873116A (en) 2021-09-29 2023-03-31 中山康方生物医药有限公司 anti-LAG 3 antibodies, pharmaceutical compositions and uses
WO2023057534A1 (en) 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
CN113912710B (en) * 2021-11-17 2023-05-26 杭州旭科生物技术有限公司 Monoclonal antibody for resisting novel coronavirus N protein and application thereof
EP4257609A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Combination therapies based on pd-1 inhibitors and sik3 inhibitors
WO2023198060A1 (en) * 2022-04-12 2023-10-19 正大天晴药业集团股份有限公司 Pharmaceutical combination of proteasome inhibitor and anti-pd-1 antibody
WO2023218046A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2023217987A1 (en) * 2022-05-12 2023-11-16 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2023217268A1 (en) * 2022-05-13 2023-11-16 正大天晴药业集团南京顺欣制药有限公司 Drug combination of anti-tim-3 antibody and anti-pd-1 antibody
WO2024051670A1 (en) * 2022-09-06 2024-03-14 正大天晴药业集团股份有限公司 Pharmaceutical combination of antibody binding to tim-3 and antibody binding to pd-1
WO2024077069A1 (en) * 2022-10-05 2024-04-11 Chulalongkorn University Monoclonal antibodies against human programmed cell death protein 1 (pd-1)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2508660C (en) * 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
EP3530672B1 (en) * 2008-09-26 2024-05-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
EP3398612A1 (en) * 2011-03-31 2018-11-07 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
HUE037651T2 (en) * 2011-04-20 2018-09-28 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
CN111499755A (en) * 2012-08-03 2020-08-07 丹娜法伯癌症研究院 anti-PD-L1 and PD-L2 double-binding antibody single reagents and methods of use thereof
CN104250302B (en) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 The anti-antibody of PD 1 and its application
SI3081576T1 (en) * 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (en) * 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
CN105175544B (en) * 2015-10-20 2021-04-09 安徽瀚海博兴生物技术有限公司 anti-PD-1 humanized monoclonal antibody and application thereof
CN105175545B (en) * 2015-10-20 2019-01-25 安徽瀚海博兴生物技术有限公司 A kind of anti-PD-1 bifunctional antibody of anti-vegf-and its application
CN106977602B (en) * 2016-08-23 2018-09-25 中山康方生物医药有限公司 A kind of anti-PD1 monoclonal antibodies, its medical composition and its use
CN106967172B (en) * 2016-08-23 2019-01-08 康方药业有限公司 The anti-PD-1 bifunctional antibody of anti-CTLA 4-, its medical composition and its use

Also Published As

Publication number Publication date
NZ751902A (en) 2022-05-27
JP7082620B2 (en) 2022-06-08
BR112019003775A2 (en) 2019-06-25
MX2019002268A (en) 2019-10-21
ZA201901781B (en) 2023-10-25
AU2017316255B2 (en) 2024-02-01
EA201990570A1 (en) 2019-08-30
IL264956A (en) 2022-12-01
EP3505535A1 (en) 2019-07-03
CN106977602B (en) 2018-09-25
US20190321466A1 (en) 2019-10-24
EP3505535A4 (en) 2020-04-15
AU2017316255A1 (en) 2019-04-11
CA3034849A1 (en) 2018-03-01
KR20190050994A (en) 2019-05-14
WO2018036472A1 (en) 2018-03-01
CN106977602A (en) 2017-07-25
JP2019534034A (en) 2019-11-28
KR102469286B1 (en) 2022-11-22
IL264956B2 (en) 2023-04-01

Similar Documents

Publication Publication Date Title
SG11201901584UA (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
MY192822A (en) An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use
NZ717213A (en) Anti-pd-l1 antibodies and their use to enhance t-cell function
MY187741A (en) Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
PH12014501783B1 (en) Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
PE20190120A1 (en) BINDING MOLECULES TO BCMA AND METHODS OF USE OF THEM
NZ612055A (en) Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
NZ706004A (en) Antibodies for treatment of cancer expressing claudin 6
NZ605980A (en) Anti-fap antibodies and methods of use
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ630433A (en) Antibodies and uses thereof to detect folate receptor 1
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
ES2687282T3 (en) ANTI-CD134 (OX40) humanized antibodies and their uses
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
NZ626269A (en) Anti-phf-tau antibodies and their uses
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
EA201490053A1 (en) ANTIBODIES THAT ARE BIND OX40 AND THEIR APPLICATION
NZ586053A (en) Anti-vegf antibody compositions and methods
MX2021001672A (en) Chimeric antigen receptor binding to hla-dr, and car-t cell.
MY196874A (en) Humanized anti-basigin antibodies and the use thereof
ES2684173T3 (en) Human anti-XCR1 antibodies
MX2016008520A (en) Novel anti-human bdca-2 antibody.
MY181914A (en) Novel anti-human ig? antibody